New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 20, 2013
04:55 EDTA, A, A, A, RHHBY, RHHBY, RHHBY, RHHBY, PKI, PKI, PKI, PKI, LIFE, LIFE, LIFE, LIFE, ILMN, ILMN, ILMN, ILMN, QGEN, QGEN, QGEN, QGEN, PACB, PACB, PACB, PACBG Corp to host a meeting
14th Annual Advances in Genome Biology and Technology Meeting is being held on Marco Island, Florida on February 20-23.
News For A;RHHBY;PKI;LIFE;ILMN;QGEN;PACB From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | all recent news | >>
October 16, 2014
13:13 EDTRHHBYRoche considers submitting Ebola test for emergency use approval, WSJ says
Subscribe for More Information
10:01 EDTILMNOn The Fly: Analyst Upgrade Summary
Subscribe for More Information
09:35 EDTRHHBYDiplomat announces contract to distribute Esbriet
Subscribe for More Information
05:58 EDTRHHBYRoche sees FY14 core EPS targeted to grow ahead of sales
Subscribe for More Information
05:56 EDTRHHBYRoche reports 9 month revenue CHF34.76B vs. CHF34.87B last year
Roche CEO Severin Schwan said: “Demand for our products is strong in both divisions and we are well on track to reach our full-year targets. We have had positive news from our product pipeline, including study results for Perjeta in breast cancer and a new combination therapy with Zelboraf in melanoma. The InterMune acquisition has also strengthened our portfolio with a new medicine, Esbriet for idiopathic pulmonary fibrosis, which has now been approved by the FDA. In Diagnostics, growth continues to be driven by the immunodiagnostics business and we have strengthened our molecular diagnostics portfolio with a new generation of testing systems.”
05:33 EDTILMNIllumina upgraded to Overweight from Neutral at Piper Jaffray
Subscribe for More Information
October 15, 2014
15:45 EDTRHHBYFDA approves Esbriet to treat idiopathic pulmonary fibrosis
Subscribe for More Information
07:43 EDTPACBPacific Biosciences releases new enhancing DNA sequencing chemistry
Subscribe for More Information
06:32 EDTILMNIllumina to invest in three genomics industry startups
Illumina selected three startup companies for the inaugural Illumina Accelerator funding cycle. The companies are Encoded Genomics, EpiBiome and Xcell Biosciences. The Illumina Accelerator will provide selected startups with seed investment, business guidance, access to Illumina’s sequencing systems and reagents, and fully operational lab space in the San Francisco Bay Area during the six-month cycle.
October 14, 2014
13:05 EDTAAgilent sees FY15 revenue declining $20M-$30M due to NMR business closure
Subscribe for More Information
13:03 EDTAAgilent sees Q4 EPS 87c-91c, consenssus 89c
Subscribe for More Information
13:02 EDTAAgilent to close Nuclear Magnetic Resonance business
Subscribe for More Information
11:23 EDTRHHBYBIND Therapeutics and The Conference Forum hold a conference
Subscribe for More Information
08:15 EDTILMNIllumina should report stronger than expected results, says Wedbush
Subscribe for More Information
October 9, 2014
10:00 EDTQGENOn The Fly: Analyst Initiation Summary
Subscribe for More Information
07:46 EDTQGENQIAGEN initiated with a Neutral at Citigroup
Target $25.
October 8, 2014
11:31 EDTRHHBYFDA grants priority review for Genentech's Lucentis
Genentech, a member of the Roche Group (RHHBY), announced that the U.S. FDA has accepted to file the company's supplemental Biologics License Application and granted Priority Review of Lucentis for the treatment of diabetic retinopathy, an eye disease that impacts nearly 7.7M Americans. The FDA confirmed action date is February 6, 2015. The sBLA was submitted August 7 to address the unmet need for approved ocular medications for the treatment of diabetic retinopathy. If approved by the FDA, Lucentis could be the first eye medicine available for diabetic retinopathy patients. The submission is based on results of the RISE and RIDE Phase III trials in which meaningful improvements in the disease were observed in a clinically significant proportion of diabetic retinopathy patients treated with Lucentis at two years compared to patients treated with sham injections. Benefits of Lucentis treatment were maintained during year three of treatment. The safety in the RISE and RIDE Phase III trials was consistent with previous studies.
10:55 EDTRHHBYLeerink pharmaceuticals analyst holds an analyst/industry conference call
Analysts discuss prospects for drugs that raise HDL cholesterol, effects of CETP mechanism, expectations for REVEAL data and the potential place for CETP inhibitors in a crowded hypersholesterolemia landscape on an Analyst/Industry conference call to be held on October 9 at 11 am.
07:19 EDTRHHBYCBI to hold a conference
Subscribe for More Information
07:18 EDTQGENInfectious Diseases Society of America to hold a conference
ID Week 2014 is being held in Philadelphia on October 8-12.
1 | 2 | 3 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use